{"id":"NCT00191113","sponsor":"Eli Lilly and Company","briefTitle":"Somatropin Treatment to Final Height in Turner Syndrome","officialTitle":"Humatrope Treatment to Final Height in Turner's Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1989-02","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2005-09-19","resultsPosted":"2010-01-27","lastUpdate":"2010-01-27"},"enrollment":154,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Turner Syndrome"],"interventions":[{"type":"DRUG","name":"Somatropin","otherNames":["Humatrope","Growth hormone"]},{"type":"DRUG","name":"Ethinyl estradiol","otherNames":[]},{"type":"DRUG","name":"Medroxyprogesterone acetate","otherNames":[]}],"arms":[{"label":"Control","type":"NO_INTERVENTION"},{"label":"Humatrope","type":"EXPERIMENTAL"}],"summary":"A randomized, controlled trial in girls with Turner syndrome at least 7 years old and younger than 13 at study entry, to determine the efficacy and safety of Humatrope (somatropin) treatment in promoting linear growth to final height.","primaryOutcome":{"measure":"Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population","timeFrame":"Baseline, and end of 4-year addendum","effectByArm":[{"arm":"As-Randomized Control","deltaMin":0.09,"sd":0.07},{"arm":"As-Randomized Humatrope","deltaMin":0.97,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"7 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":14,"countries":["Canada"]},"refs":{"pmids":["4062345","11183293","16757526","15784709","21619701"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":54},"commonTop":["Cold","Headache","Sore throat","Fever","Flu"]}}